Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,527,535
  • Shares Outstanding, K 60,765
  • Annual Sales, $ 4,069 M
  • Annual Income, $ 560,120 K
  • EBIT $ 150 M
  • EBITDA $ 810 M
  • 60-Month Beta 0.26
  • Price/Sales 2.55
  • Price/Cash Flow 5.67
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 41.43% (+7.01%)
  • Historical Volatility 20.51%
  • IV Percentile 61%
  • IV Rank 35.90%
  • IV High 69.53% on 08/05/25
  • IV Low 25.70% on 02/28/25
  • Expected Move (DTE 24) 10.80 (6.21%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,079
  • Volume Avg (30-Day) 480
  • Put/Call OI Ratio 1.59
  • Today's Open Interest 11,736
  • Open Int (30-Day) 10,598
  • Expected Range 163.04 to 184.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 5.65
  • Number of Estimates 7
  • High Estimate 6.60
  • Low Estimate 5.09
  • Prior Year 5.70
  • Growth Rate Est. (year over year) -0.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
161.38 +7.71%
on 02/11/26
174.00 -0.10%
on 02/23/26
+5.12 (+3.03%)
since 01/23/26
3-Month
156.95 +10.76%
on 01/08/26
182.75 -4.88%
on 11/25/25
-7.07 (-3.91%)
since 11/24/25
52-Week
95.49 +82.04%
on 04/09/25
182.99 -5.01%
on 11/18/25
+37.14 (+27.17%)
since 02/24/25

Most Recent Stories

More News
Jazz: Q4 Earnings Snapshot

Jazz: Q4 Earnings Snapshot

JAZZ : 173.83 (+0.33%)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales

JAZZ : 173.83 (+0.33%)
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –

JAZZ : 173.83 (+0.33%)
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

Jazz Pharmaceuticals Earnings: What To Look For From JAZZ

JAZZ : 173.83 (+0.33%)
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

DUBLIN , Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor conferences:

JAZZ : 173.83 (+0.33%)
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

JAZZ : 173.83 (+0.33%)
ELV : 327.14 (-2.60%)
FBRT : 8.83 (-1.78%)
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Avoid

JAZZ : 173.83 (+0.33%)
ZS : 149.36 (+4.24%)
NVST : 29.43 (+1.55%)
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

DUBLIN , Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after...

JAZZ : 173.83 (+0.33%)
3 Cash-Producing Stocks We Think Twice About

3 Cash-Producing Stocks We Think Twice About

JAZZ : 173.83 (+0.33%)
JACK : 17.41 (+1.99%)
ZBRA : 235.83 (+1.95%)
3 of Wall Street’s Favorite Stocks We Think Twice About

3 of Wall Street’s Favorite Stocks We Think Twice About

CARS : 10.66 (+0.47%)
PENN : 12.72 (+4.52%)
JAZZ : 173.83 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 177.03
2nd Resistance Point 175.48
1st Resistance Point 174.66
Last Price 173.83
1st Support Level 172.29
2nd Support Level 170.74
3rd Support Level 169.92

See More

52-Week High 182.99
Last Price 173.83
Fibonacci 61.8% 149.57
Fibonacci 50% 139.24
Fibonacci 38.2% 128.91
52-Week Low 95.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar